<DOC>
	<DOCNO>NCT01926782</DOCNO>
	<brief_summary>To determine efficacy , long-term safety , tolerability alirocumab 300 mg every 4 week ( Q4W ) , comparison placebo , well potential start regimen . The dose regimen 75 mg every 2 week ( Q2W ) , used study , add calibrator .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety Every Four Weeks Treatment Regimen Alirocumab ( REGN727/ SAR236553 ) Patients With Primary Hypercholesterolemia ( ODYSSEY CHOICE 1 )</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<criteria>1 . Men woman &gt; age 18 legal age majority elevate LDLC 2 . Patients adequate control hypercholesterolemia base individual level CVD risk 3 . Willing able comply clinic visit studyrelated procedure 4 . Provided sign informed consent 1 . Recent ( within 3 month prior screen visit ) myocardial infarction , unstable angina lead hospitalization , percutaneous coronary intervention ( PCI ) , coronary artery bypass graft surgery ( CABG ) , uncontrolled cardiac arrhythmia , stroke , transient ischemic attack , carotid revascularization , endovascular procedure surgical intervention peripheral vascular disease 2 . Known history positive test human immunodeficiency virus ( HIV ) 3 . Any clinically significant abnormality identify time screen judgment investigator subinvestigator would preclude safe completion study constrain assessment endpoint , major systemic disease participant short life expectancy . 4 . Participants consider investigator subinvestigator inappropriate study ( e.g , geographic social ) , actual anticipate , investigator felt would restrict limit participant 's participation duration study . 5 . Certain laboratory finding obtain screen period The information list intend contain consideration relevant participant 's potential participation clinical trial inclusion/ exclusion criterion list .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>